Early Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with pancreatic cancer (including adenocarcinoma or other types of malignant pancreatic tumors) confirmed through tissue or cell testing
- People who have at least one tumor that can be measured using medical imaging
- People whose cancer was initially thought to be removable by surgery, but during early surgical exploration was found to have spread to other parts of the body
- People who have read, understood, and signed the consent form approved by the relevant ethics review board
- People who have previously received treatments for advanced cancer, such as chemotherapy, targeted therapy, hormonal therapy, or experimental treatments
Who may not be able to join:
- People with a physical health status rated above level 3 on the ASA scale, meaning those considered to be in very poor overall health before any procedure (confirm with trial site)
- People who have a known allergy or sensitivity to a type of local anesthetic called amide-linked anesthetics (examples include lidocaine-type medications)
- People who have a second or third degree heart block, which is a condition affecting the electrical signals in the heart
- People who have a severe blockage in the heart's natural pacemaker area (severe sinoatrial block)
- People currently taking certain heart rhythm medications, specifically quinidine, flecainide, disopyramide, or procainamide
- People who have ever been treated with a heart medication called amiodarone
- People who have Adams-Stokes syndrome, a condition involving sudden loss of consciousness related to the heart
- People who have Wolff-Parkinson-White syndrome, a condition involving an extra electrical pathway in the heart
- People with a history of blood clots, pulmonary embolism, or deep vein thrombosis that is not being managed with blood-thinning medication
- People with a known history of HIV, or untreated and uncontrolled hepatitis B or C
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gina E. Votta-Velis, MD PhD, Associate Professor
Phone: (312)996-4020
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Specimen outcome measure.; Specimen outcome measure.; Specimen outcome measure.; Upregulation or Downregulation of Gene Expression.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.